Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Reduced gingival fluid flow: a peripheral marker of the pharmacological effect of roquinimex

Reduced gingival fluid flow: a peripheral marker of the pharmacological effect of roquinimex Objective: Roquinimex is a drug with effects on inflammation and tumors. The pharmacological effect is not fully understood, and the molecular mechanism most characterized in vitro is an increase of plasminogen activator inhibitor type 2 (PAI-2) in human peripheral blood monocytes. The aims were to investigate peripheral pharmacological effects of roquinimex on peripheral blood monocytes and dog gingival fluid (GCF).___TAGSTART___BR___TAGEND___ Design: Six dogs were used in a cross-over study. The amount of GCF was determined with a Periotron®. The PAI-2 concentration in GCF was determined with ELISA. Monocytes were isolated from peripheral blood.___TAGSTART___BR___TAGEND___ Results: Dogs treated with the drug had significantly lower GCF flow values and the PAI-2 concentration in GCF was higher, but no effect was seen on peripheral monocytes.___TAGSTART___BR___TAGEND___ Conclusion: Roquinimex treatment led to a consistently decreased flow rate of GCF and a higher local concentration of PAI-2 in GCF. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Inflammopharmacology Springer Journals

Reduced gingival fluid flow: a peripheral marker of the pharmacological effect of roquinimex

Loading next page...
 
/lp/springer-journals/reduced-gingival-fluid-flow-a-peripheral-marker-of-the-pharmacological-OtdBJeTvio

References (44)

Publisher
Springer Journals
Copyright
Copyright © 2003 by VSP 2003
Subject
Biomedicine; Pharmacology/Toxicology; Allergology; Rheumatology
ISSN
0925-4692
eISSN
1568-5608
DOI
10.1163/156856003322315613
pmid
15035809
Publisher site
See Article on Publisher Site

Abstract

Objective: Roquinimex is a drug with effects on inflammation and tumors. The pharmacological effect is not fully understood, and the molecular mechanism most characterized in vitro is an increase of plasminogen activator inhibitor type 2 (PAI-2) in human peripheral blood monocytes. The aims were to investigate peripheral pharmacological effects of roquinimex on peripheral blood monocytes and dog gingival fluid (GCF).___TAGSTART___BR___TAGEND___ Design: Six dogs were used in a cross-over study. The amount of GCF was determined with a Periotron®. The PAI-2 concentration in GCF was determined with ELISA. Monocytes were isolated from peripheral blood.___TAGSTART___BR___TAGEND___ Results: Dogs treated with the drug had significantly lower GCF flow values and the PAI-2 concentration in GCF was higher, but no effect was seen on peripheral monocytes.___TAGSTART___BR___TAGEND___ Conclusion: Roquinimex treatment led to a consistently decreased flow rate of GCF and a higher local concentration of PAI-2 in GCF.

Journal

InflammopharmacologySpringer Journals

Published: Dec 22, 2004

There are no references for this article.